Imparare a tradurre dagli esempi di traduzione forniti da contributi umani.
Da: Traduzione automatica
Suggerisci una traduzione migliore
Qualità:
Da traduttori professionisti, imprese, pagine web e archivi di traduzione disponibili gratuitamente al pubblico.
imlygic talimogeenlaherparepvek
imlygic talimogene laherparepvec
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità:
toimeaine on talimogeenlaherparepvek.
the active substance is talimogene laherparepvec.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità:
imlygic’u toimeaine on talimogeenlaherparepvek.
the active ingredient of imlygic is talimogene laherparepvec.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità:
talimogeenlaherparepvek on tundlik atsükloviiri suhtes.
talimogene laherparepvec is sensitive to acyclovir.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità:
ei ole teada, kas talimogeenlaherparepvek eritub rinnapiima.
it is unknown whether talimogene laherparepvec is transferred into human milk.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità:
talimogeenlaherparepvek on onkolüütiline immuunravim, mis on hsv-1 derivaat.
talimogene laherparepvec is an oncolytic immunotherapy that is derived from hsv-1.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità:
talimogeenlaherparepvek on geneetiliselt muundatud ja replikatsioonivõimeline hsv-1 viirus.
talimogene laherparepvec is a genetically modified and replication-competent hsv-1 virus.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità:
talimogeenlaherparepvek lagundatakse endogeense valgu ja dna tüüpilises kataboolses rajas.
talimogene laherparepvec is degraded by typical endogenous protein and dna catabolic pathways.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità:
imlygici toimeaine talimogeenlaherparepvek on geeniteraapiaravimite tüüp, mida nimetatakse onkolüütiliseks viiruseks.
the active substance in imlygic, talimogene laherparepvec, is a type of gene therapy called ‘oncolytic virus’.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità:
talimogeenlaherparepvek eemaldatakse retsipiendi üldiste kaitsemehhanismide poolt (nt autofaagia, adaptiivne immuunvastus).
talimogene laherparepvec is cleared through general host-defence mechanisms (e.g. autophagy, adaptive immune responses).
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità:
talimogeenlaherparepvek on modifitseeritud replitseeruma kasvaja sees ja tootma immunostimuleerivat valku, inimese gm-csf’i.
talimogene laherparepvec has been modified to replicate within tumours and to produce the immune stimulatory protein human gm-csf.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità:
talimogeenlaherparepvek siseneb kasvajalistesse ja mittekasvajalistesse rakkudesse nende pinnal paiknevate hsv-1 retseptorite vahendusel pärast paikset süstimist kasvajasse.
cellular uptake of talimogene laherparepvec occurs through hsv-1 receptors on tumours and non- tumour cells following local injection into tumours.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità:
kliinilised andmed talimogeenlaherparepvek’i infektsioonidest rasedatel puuduvad, kuid võib eksisteerida oht lootele või vastsündinule, kui talimogeenlaherparepvek toimib samal viisil.
while there are no clinical data to date on talimogene laherparepvec infections in pregnant women, there could be a risk to the foetus or neonate if talimogene laherparepvec were to act in the same manner.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità:
talimogeenlaherparepvek on ette nähtud sisenema kasvajakoesse ja seal paljunema, mistõttu eksisteerib oht, et loode puutub talimogeenlaherparepvek’iga kokku platsentat läbinud kasvajakoe kaudu.
because talimogene laherparepvec is designed to enter and replicate in the tumour tissue, there could be a risk of foetal exposure to talimogene laherparepvec from tumour tissue that has crossed the placenta.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità:
imlygic 106 lüüsilaiku moodustavat ühikut (pfu)/ml, süstelahus imlygic 108 lüüsilaiku moodustavat ühikut (pfu)/ml, süstelahus talimogeenlaherparepvek
imlygic 106 plaque forming units (pfu)/ml solution for injection imlygic 108 plaque forming units (pfu)/ml solution for injection talimogene laherparepvec
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità:
talimogeenlaherparepvek on nõrgestatud 1. tüüpi lihtherpesviirus (hsv-1, herpes simplex virus type- 1), mis on saadud 2 geeni (icp34.5 ja icp47) funktsionaalse deletsiooni ja inimese granulotsüütide- makrofaagide kolooniaid stimuleerivat faktorit (gm-csf) kodeeriva järjestuse sisestamise teel (vt lõik 5.1).
talimogene laherparepvec is an attenuated herpes simplex virus type-1 (hsv-1) derived by functional deletion of 2 genes (icp34.5 and icp47) and insertion of coding sequence for human granulocyte macrophage colony-stimulating factor (gm-csf) (see section 5.1).
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità: